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Accepted 18 December 2013The deﬁnition of interstitial cystitis (IC) has evolved to include
painful bladder syndrome (PBS) in the past few years. IC is a syn-
drome characterized by “the complaint of suprapubic pain related
to bladder ﬁlling, accompanied by other symptoms such as
increased day- and nighttime frequency, in the absence of proven
urinary infection or other obvious pathology” [1]. However, the
signs and symptoms of IC/PBS early in the course of disease may be
intermittent and variable, making IC/PBS difﬁcult to recognize [2].
Overactive bladder (OAB), which was recently deﬁned by the
International Continence Society as “urinary urgency, usually
accompanied by frequency and nocturia, with or without urinary
urgency incontinence, in the absence of urinary tract infection or
other obvious pathology” [3], is one of several disorders that have
the same cluster of symptoms as IC/PBS. Therefore, it is sometimes
not easy to differentiate IC and OAB on the basis of clinical pre-
sentation alone.
However, the conventional therapies used for each diagnosis
address different pathophysiological mechanisms [4,5]. It is crucial
to establish the correct diagnosis prior to embarking on any
extended treatment protocol. Many clinicians have used the pres-
ence of urodynamic detrusor overactivity (DO) as a criterion to
exclude the diagnosis of IC [6]. However, recent studies and surveys
suggest the possibility that two conditions may exist concurrently
[7]. Investigators have suggested that some patients diagnosed
with OAB, particularly those refractory to treatment with anti-
muscarinics, may have IC [8e11].* Corresponding author. Department of Obstetrics and Gynecology, Taichung
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1028-4559/Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. PublishedWe report a patient with refractory OAB who also had cysto-
scopic ﬁndings of IC. The purpose of this study was to investigate
the possibility that the two conditions may occur concurrently. The
ﬁndings indicate that some patients refractory to one of the two
therapies require further evaluation and treatment.
A 35-year-old woman, gravida 3, para 3, presented with urinary
frequency, urgency, and urgency incontinence, which had plagued
her for several years. She had undergone a Cesarean section for her
third baby 7 years ago, and experienced these symptoms shortly
after the operation. In the past 2 years, she also noticed a dull lower
abdominal pain accompanied with a bearing-down sensation. She
tried several medications prescribed by other doctors including
Solifenacin (Vesicare; Astellas Pharma, Leiderdorp, Netherlands,
Europe), and Tolterodine (Detrusitol; Pﬁzer Pharma, Winchester,
Kentucky, USA), but symptoms persisted and she decided to visit
our hospital.
A pelvic examination revealed a normal-sized uterus with
adhesion to the right abdominal wall. The patient reported mild
tenderness while the uterus was being lifted. The fre-
quencyevolume chart revealed she had to void a volume of
70e150 mL every 30e60 minutes. Sometimes she also experienced
urine incontinence when she rushed to the bathroom. The urinal-
ysis report was normal, except for the presence of a few red blood
cells (RBC 2e5 in HPF). The urodynamic study revealed phasic and
terminal DO. Frequent and involuntary detrusor contractions
occurred during ﬁlling cystometry (Fig. 1), accompanied with urine
incontinence. The ﬁrst desire to void was at 18 mL, and her cysto-
metric capacity was only 60 mL. Owing to the patient's poor
response to antimuscarinic drugs, we arranged diagnostic lapa-
roscopy and cystoscopy. We noticed bladder adhesion to the lower
segment of the uterus during the laparoscopic examination (Fig. 2),
and adhesion lysis was performed. Cystoscopy showed diffuse
(grade III) glomerulations and marked terminal hematuria (Fig. 3).
Thereafter, the patient received cyclic hyaluronic acid bladder
instillation therapy (4 weekly intravesical instillations of 40 mg of
hyaluronic acid followed by 5 monthly instillations), with
concomitant antimuscarinics (Oxbu extended-release, 5 mg QDby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Phasic and terminal detrusor overactivity on ﬁlling cystometry.
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dramatically improved from voiding every 30 minutes to once
every 1e2 hours. She was very satisﬁed with the decrease in urine
incontinence. Furthermore, the lower abdominal pain also sub-
sided dramatically after the therapy.
In this study, we present a case of an underdiagnosis inwhich no
effective treatment had been found by previous clinicians, and
who was ultimately diagnosed with IC and OAB as well as pelvic
adhesion. Concomitant cystoscopy and laparoscopy, as well as a
comprehensive urodynamic study, led to the ﬁnal diagnosis andFig. 2. Bladder adhesion to the lower segment of the uterus due to previous cesarean
section (white arrows).enhanced the complete treatment. The patient is currently in a
stable condition and is receiving multiple treatments.
Female lower urinary tract symptoms are categorized into
different syndromes based on combinations of symptoms [1,3].
OAB and PBS were formally deﬁned in 2002 by the International
Continence Society [1]. Both have the symptoms of frequency, ur-
gency, and nocturia, but the core symptoms are different. Supra-
pubic pain accompanied with bladder ﬁlling is the hallmark
symptom of PBS. By contrast, urgency with or without urgency
incontinence is considered to be the core symptom of OAB. For
most typical patients, symptomatic diagnosis and empirical treat-
ment are adequate. But for patients with atypical symptoms or
nonresponders, it is important to verify the symptoms using spe-
ciﬁc methods, such as urodynamic study for detection of DO, or
cystoscopy for evaluation of IC signs. Under such circumstances,
clinicians can establish a second diagnosis and develop alternative
treatment strategies.
For decades, IC/PBS and OAB/DO were thought to exclude one
another in differential diagnosis because the underlying patho-
physiologies are different. The National Institute of Digestive and
Kidney Diseases formulated strict criteria for diagnosis of IC in
1988, encompassing the inclusion and exclusion criteria that
describe the syndrome and identify a relatively homogeneous pa-
tient population [12]. Therefore, many clinicians have used the
presence of DO as a criterion to exclude the diagnosis of IC [6], but
there is no widespread consensus on its use [7]. However, in many
OAB studies, bladder pain and/or IC are exclusionary criteria and
pain has rarely been measured in OAB patients [13e15].
Nonetheless, it is still possible that a patient may have the two
conditions concurrently. For example, several investigators had
suggested that the prevalence of IC in patients with DO that does
not respond to treatment with anticholinergic medications is high
Fig. 3. Glomerulation on cystoscopy.
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DO were sensitive to intravesical potassium. Another prospective
cohort study showed that 60% of patients with OAB symptoms have
a positive potassium sensitivity test result [9]. By contrast, several
studies have suggested that a portion of IC patients have evidence
of DO based on the results of urodynamic analysis. In 1997, the
Interstitial Cystitis Database study group reported that approxi-
mately 15% of patients with IC have spontaneous DO as measured
by urodynamic testing [16]. Hung et al [17] reported that 54% of IC
patients had bladder oversensitivity and 8.1% had DO. The results of
the present case support these apparently overlapping conditions.
As the diagnosis of OAB or PBS is symptom-based, it must be
realized that not all patients will respond to the initial manage-
ment. When this occurs, the clinician must recognize that other
causes need to be considered, and this will lead to new treatment
options. For refractory OAB patients, it is necessary to take the
diagnosis of IC into consideration and to add a suitable bladder
instillation therapy. By contrast, IC patients usually have a reduced-
capacity bladder that is in part responsible for their need to urinate
at low volumes [18,19]. The therapeutic efﬁcacy of urinary symp-
toms for these patients is usually not very promising when using
the standard intravesical therapy alone [20]. In this circumstance,
IC patients might show clinical improvement after the addition of
OAB treatment, such as anticholinergic therapy and bladder
training.
Our case not only had IC and OAB concomitantly, but also had
pelvic adhesion. We performed diagnostic laparoscopy and
cystoscopy to establish the cause of the refractory urinary symp-
toms and chronic pelvic pain (CPP), and were thus able to establish
the above diagnosis at the same time. It is well known that chronic
pain in patients who have previously received surgery may be due
to postoperative adhesions. Historically, IC was rarely considered as
a cause of CPP, but recent data suggest that IC is a relatively com-
mon cause of CPP in gynecologic patients [21,22]. It is important to
consider the bladder as a generator of symptoms early in the
evaluation of gynecologic patients with CPP. By determining
whether the bladder is the origin of the pain, the patient can be
more successfully treated. Our patient experienced immediate
postoperative relief of pelvic pain owing to adhesion lysis and
bladder hydrodistension. For more sustained and better pain res-
olution, however, continued treatment for IC such as cyclic bladder
instillation is more effective.
In conclusion, OAB and IC can present with similar symptoms,
such as urinary urgency, frequency, and nocturia. Both OAB and IC,
therefore, should be included in the differential diagnosis for pa-
tients who present with a hypersensitive bladder. The possibility
that two conditions may occur concurrently is high, especially in
patients who are refractory to traditional therapy. If the initialtreatment does not result in a signiﬁcant remission of symptoms,
further investigation to identify the concurrence of other diseases is
indicated.Conﬂicts of interest
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